A REVIEW ARTICLE ON THE EFFECTIVENESS OF ANTI - INFLAMMATORY DRUGS IN MANAGING RHEUMATOID ARTHRITIS

Mrigank Verma*, Aarti Sati
Department of Pharmaceutical Sciences
Shri Guru Ram Rai Institute of Medical Sciences and Technology,
Dehradun (Uttrakhand) India

Abstract: ***Rheumatoid Arthritis commonest inflammable arthropathy, with the increase in age frequency of new cases are rapidly increasing every year. Non-steroidal anti-inflammatory drugs such as methotrexate, Diclofenac, Aspirin and many others are commonly used for the treatment of Rheumatoid arthritis. The drug Methotrexate to be used earlier at a progressive assessment for less apparent clinical changes and less development of damage in rheumatoid arthritis. Leflunomide was convincing in step by step estimations of 10mg and 25mg in patients with dynamic rheumatoid arthritis, as shown up by authentically necessary change over phony treatment in primary and optional outcome measures. Ridaura decreasing rheumatoid irritation is suggested by expects itemizing an impact of these professionals on the Rheumatoid factor. The ability of NSAIDs to thereby inhibit the activation of inflammatory cells such as the neutrophil may contribute to the anti-inflammatory properties of this class of drugs.***

KEYWORDS: Rheumatoid Arthritis, Anti Inflammatory Drugs, MOA of NSAIDs and their Effectiveness, New Methods for the treatment of Rheumatoid Arthritis.

INTRODUCTION

Rheumatoid arthritis (RA) is a constant, relapsing immune system challenging disease, that is described by irritation, synovial layer irritation and confined joint development because of tissue harms[1], rheumatoid arthritis is described clinically by joint pain, stiffness, and swelling because of synovial irritation and radiation, by standing out from different types of joint pain, rheumatoid joint inflammation synovitis has a high tendency to ignore tissue limits, penetrating articular bone and ligament (at that point called pannus). The disease causes inability (with loss of working restrict and early retirement) and sudden passing if deficiently treated.[2, 3]

It has been now distinguished that joint damage happens especially before time in rheumatoid arthritis, and by two years around 60% of patients will exhibit some radiographic confirmation of disintegrations[4]. Rheumatoid arthritis is an initial inflammable illness of incomprehensible reason and has an around the world commonness of 1%. Rheumatoid arthritis is 2– 3 times more typical in ladies, with apex beginning between ages 30 and 55 years. Irritation happens symmetrically in the synovial covering of the joints, ligaments, and periarticular structures. Left untreated, rheumatoid arthritis prompts joint destruction, effective confinements, severe inability, and diminished future[5].

BACKGROUND

The conspicuous central portrayal of rheumatoid arthritis was made in 1800 by Dr Augustin Jacob Landre-Beauvais (1772-1840) of Paris[6]. According to the remains of Neanderthal man, a relative of modern man, who made his first appearance between 30,000 BC and 28,000 BC, individuals of this time developed secondary osteoarthritis due to injuries and the difficulties of daily life[7,8]. Thus, there is evidence that arthritis has been in this world since the beginning of civilisation, which makes it one of the oldest diseases in the universe. Arthritis was evidenced in ancient Ötzi, name given to a mummy, popularly known as the Iceman, who attempted to cross the Alps near the border of Italy and Austria in 3000BC. Although he was not successful in his venture, the mummified remains of his body, with the pouch of medicinal herbs that he carried with him, and his arthritic joints, provide valuable information even 5000 years after his death[9].

SIGN AND SIDE EFFECTS

In Rheumatoid Arthritis Pain and solidness were going on for over 30 minutes early in the day or after an extended rest. Joints are tender, warm and swollen and aggravation in joints is frequently influencing the wrist and finger joints nearest to the hand and other affected joints can incorporate those of the neck, shoulders, elbows, hips, knees, lower legs, and feet as example for instance, on the possibility that one knee is influenced, the other one is too, Fatigue, infrequent fever, a general feeling of not feeling admirable (disquietude) and the Symptoms of rheumatoid arthritis are influencing different parts of the body other than the joints[10].

RARER CAUSES THAT MAY CAUSE RHEUMATOID ARTHRITIS

Sarcoidosis, amyloidosis, and Whipple's sickness can likewise look like rheumatoid arthritis; Hemochromatosis may cause hand joint pain; intense rheumatic fever can be separated from rheumatoid arthritis by a temporary example of joint contribution and confirmation of precursor streptococcal contamination; Bacterial joint inflammation, (for example, streptococcus) is generally Hitler kilter, while RA, as a rule, includes the two sides of the body symmetrically; Gonococcal joint inflammation (another bacterial joint inflammation) is additionally at first transitory and can consist of ligaments around the wrists and ankles[11].

INFLAMMATION

Aggravation assumes a remarkable part in the pathophysiology of a wide range of sicknesses. It is a defensive reaction, yet if excessive or improperly drawn out can contribute antagonistically to the disease procedure. Therefore, anti-inflammatory drugs are broadly utilized. Some drugs are easily available in the market which shows protected anti-inflammatory effects, yet they are a two-edged sword and powerful calming medications which can have extreme unfavorable impacts. The impacts which are not in favor is because of two things are as follows-

1:- Fiery cells: a wide range of cells are involved with various phases of various types of fiery reaction, including neutrophils (e.g. in intense bacterial diseases), eosinophils, pole cells and lymphocytes e.g. in asthma, monocytes, macrophages and lymphocytes (for instance, in immune system vasculitic illness, including persistent joint infections, for example, rheumatoid joint inflammation and the thrombosis.

2:- Fiery arbiters: incorporate prostaglandins, complement, and coagulation-course determined peptides, and cytokines (for illustration, interleukins, particularly IL-2 and IL-6, and tumor rot factor (TNF) [12].

NON STEROIDAL ANTI INFLAMMATORY DRUGS

Non-steroidal anti-inflammatory drugs (NSAIDs) block prostaglandin biosynthesis by limiting cyclooxygenase (COX). This is the start of most of their therapeutic and their undesired exercises. COX is a critical creation in the mix of prostaglandins and thromboxane essential center individuals of the erythema, edema, misery, and fever of disturbance. There are two standard isoforms of the substance, specifically a constitutive shape (COX-1), that is accessible in platelets, stomach, kidneys and diverse tissues, also, an inducible form, (COX-2)[12].

ASPIRIN

MECHANISM OF ACTION

Aspirin applies its impact principally by interfering with the biosynthesis of cyclic prostanoids, i.e., thromboxane A2 (TXA2), prostacyclin, and different prostaglandins. These prostanoids are produced by the enzymatically catalyzed oxidation of arachidonic corrosive, which is itself gotten from film phospholipids[13]. Arachidonic corrosive is processed by the compound prostaglandin (PG) H-synthase, which, through its cyclooxygenase (COX) and peroxidase exercises, comes about in the creation of PGG2 and PGH2, individually. PGH2 is at that point changed by particular synthases, in this way creating prostaglandins D2, E2, F2a, I2 (prostacyclin), and TXA2, all of which intercede in specific cell capacities. PGH-synthase likewise alluded to as COX, exists in 2 isoforms that have a critical homology of their amino corrosive sequences[14]. A single amino corrosive substitution in the reactant site of the protein presents selectivity to inhibitors of the COX isoforms[15,16]. The principal isoform (COX-1) is constitutively communicated in the endoplasmic reticulum of most cells (counting platelets)[17.] And brings about the blend of homeostatic prostaglandins in charge of ordinary cell capacities, including gastric mucosal assurance, upkeep of renal bloodstream, what's more, control of platelet initiation and aggregation[18]. The second isoform (COX-2) isn't routinely present in most mammalian cells at the same time, instead, is quickly inducible by fiery boosts and development factors and results in the creation of prostaglandins that add to the incendiary response[19,20]. Aspirin gives its essential antithrombotic impacts through the hindrance of PGH-synthase/COX by the irreversible acetylation of a particular serine moiety (serine 530 of COX-1 also, serine 516 of COX-2)[21,22], and is '170-overlay more strong in repressing COX-1 than COX-2[23]. Within sight of headache medicine, COX-1 is inactivated, while COX-2 changes over arachidonic corrosive not to PGH2, but rather to 15-R-hydroxyeicosatetraenoic corrosive (15-R-HETE)[24]. The final product is that not one or the other influenced isoform is equipped for changing over arachidonic corrosive to PGH2, a significant advance in the creation of prostanoids. The resultant diminished production of prostaglandins and TXA2 likely records for the remedial impacts, and additionally the toxicities, of headache medicine.

THE EFFECTIVENESS OF ASPIRIN IN RHEUMATOID ARHTIRIS

High-dosage of aspirin, once mostly prescribed drugs, the use of low-dose and very low-dose (low than usual dose) headache medicine for the dislike of thrombosis has been significantly expanded during the most recent period. Current utilization of aspirin in the US is assessed to be 10,000– 20,000 tons for every year[25], and in Israel, with a populace of; 6 million, 5 tons of the 100-mg enteric covered readiness alone were distributed a mid-1997. The medication is taken, regularly as an over-the-counter cure, by numerous patients, and by healthy subjects also. Those investigators found that while ibuprofen measurements of .3gm/day tend to advance uricosuria, bring down doses (1– 2gm/day) may cause rheumatoid arthritis maintenance. The impacts of mini-dose headache medicine (,0.5 gm/day) on this bimodal phenomenon have not been considered, nor have its consequences for basal renal work. Elderly subjects might be at higher hazard for diclofenac and headache medicine encouraged antagonistic impacts in general and for rheumatoid arthritis specifically[26,27].

SIDE EFFECTS OF ASPIRIN

Recently, after reports that aspirin may reduce the mortality and recurrence of rheumatoid arthritis. Aspirin has been appeared to interfere with platelet function to make unfavorably susceptible responses in the delicate instigate peeling of renal epithelial cells to start gastric and to fuel duodenum ulcer and disturb liver infection. Headache medicine has been uproariously complained as causing gastric disappearing. Headache medicine increments tiny blood trouble from the gut[28].

DICLOFENAC

MECHANISM OF ACTION

Diclofenac blocks the combination of proinflammatory also, nociceptive prostaglandins in blood and synovial tissue[29,30,31]. Diclofenac is among the best inhibitors of prostaglandin E2 (PGE2) generation and has been accounted for to be 3 to 1000 times more strong on a molar evidence compared and different NSAIDs in its ability to delay COX activity[32,33]. PGE2 limitation by diclofenac is associated with anaesthetize obsession in the plasma[34]**.** The clarification of particular isoforms of COX has advanced the comprehension of this class of catalysts and its capacity to confine prostaglandin incorporation. COX-1 is considered to be the 'housekeeping' isoform that is constitutively communicated in most tissue composes. COX-1 focus remains moderately stable and is included with intervening typical platelet work, managing renal bloodstream, and giving cytoprotection of the gastric mucosa using prostaglandin I2 (prostacyclin)[35]. Conversely, the statement of COX-2 can

severely increment in reaction to tissue harm, and proinflammatory arbitrators also are in charge of the expanded creation of prostaglandin, thromboxane, and leukotriene mediators of irritation also causing pain[35,36].

THE EFFECCTIVENESS OF DICLOFENAC

Effectiveness of topical diclofenac in the treatment of rheumatoid arthritis, in which thirty subjects with acute rheumatoid arthritis (<4 weeks' duration) demonstrated significant 2% diclofenac in PLO appears to provide an adequate short-term reduction in elbow pain and wrist extensor[37].

SIDE EFFECTS OF DICLOFENAC

Diclofenac diffuses into the sub dermal tissue. It is a slight lipophilic atom that has been appeared to be fit for quick distribution through the skin and to take in blood, muscle interstitial tissue, and synovial liquid. The general skin disturbance and erythema were seen fundamentally less as often as possible in the treatment bunch as the control gathering ($P < 0.05$). Diclofenac observed unfavorable impact in either gather was skin aggravation: with 16%-18% in the control gathering furthermore, 3%-6% in the treatment gathering. In any case, every antagonistic impact had quickly and unpredictably stable before the finish of this examination without any treatment[38].

METHORTREXATE

MECHANISM OF ACTION

Methotrexate may influence cell absorption at certain many advances. Other than the aggressive interruption of dihydrofolate reductase, its great method of activity, it might similarly block thymidylate synthetase also, transmethylation of proteins. It might similarly interfere with all over again purine biosynthesis by interference of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase, a protein in the purine biosynthetic pathway[39].

THE EFFECTIVENESS OF METHOTREXATE

In Fifty-nine patients treated with methotrexate for two years were notable. The mean age was 46 years, PsA term eight years, and dynamic joint count 12.1 (4.6 swollen). The mean increase in radiographic harm score was 1.5. Sixty-eight per cent of patients exhibited change at two years. At the point when contrasted with our past examination, there was a pattern for methotrexate to be utilized before, at a higher measurement, with more visible clinical change and less movement of harm[40].

SIDE EFFECT OF METHOTREXATE

No hazardous reactions happened. Symptoms happened in 62% and 45% of patients treated with methotrexate and methotrexate + CS, separately. Methotrexate treatment must be ceased in six patients [methotrexate, methotrexate+CS], because of severe symptoms, including infections, gastrointestinal reactions still, raised liver catalysts. Methotrexate was restarted in four of these six patients, with no repeat of symptoms[41].

LEFLUNOMIDE

MECHANISM OF ACTION

Leflunomide to restrict the catalyst Dihydroorotate dehydrogenase, a key chemical in the pathway for a new combination of rUMP[42]. Pyrimidine ribonucleotides, (for example, rUMP) can be become from either a new combination paths that require DHODH or from rescue pathways that are autonomous of Dihydroorotate dehydrogenase. Since passed lymphocytes need approximately an eightfold increment in their levels of Backend (and other pyrimidine ribonucleotides) all together to advance from gastrointestinal through the period of the cell cycle, they should use both again pyrimidine and release pathways of pyrimidine ribonucleotide combination[43]. At the point when hindrance of Dihydroorotate dehydrogenase by A77-1726 counteracts generation of rUMP by the all over again union pathway, the initiated lymphocyte experiences a capture in the G1 period of the cell cycle[44,45]. As a result, leflunomide can repress immune system T-cell multiplication furthermore, generation of autoantibodies by B-cells[46,47].

THE EFFECTIVENESS OF LEFLUNOMIDE

Leflunomide is significant in day by day measurements of 10 mg and 25 mg in patients with dynamic RA. Improved viability at the 25-mg dosage was related with a higher frequency of adverse drug events. Leflunomide was convincing in day by day measurements of 10 mg and 25 mg in patients with dynamic RA, as appeared by accurately critical change over false treatment in essential and optional result measures, and also by responder examinations. Although improved adequacy was seen with the 25-mg measurement, it was related to a higher occurrence of unfavorable incidents. These positive outcomes permit affirmation in bigger randomized, false treatment controlled trials[48].

SIDE EFFECTS OF LEFLUNOMIDE

The most basic side effect of leflunomide is looseness of the bowels and liver harmfulness. Most examples of liver lethality are seen inside a half year of treatment, when different risk factors are available (hepatotoxic, past liver illnesses) in rheumatoid arthritis. The indication of liver risk ranges from mild jaundice to severe unchanging hepatitis are the extreme liver deterioration and liver cirrhosis. During the treatment of rheumatoid arthritis when bone marrow density will decreased resulting patients suffering with Anemia, leukopenia and thrombocytopenia. Other side effects are related to skin is Life-undermining Stevens-Johnson disorder or on the other hand Toxic epidermal necrolysis, skin break out discharges, hair staining, alopecia, maculopapular rash and nail discoloration seen in under 1% of patients. Respiratory disease with Pneumocystis jiroveci furthermore, Aspergillus which shows as nonreversible asthma and dyspnea. Other symptoms are CVS (angina, palpitation), CNS (uneasiness, melancholy and a sleeping disorder) [49].

RAIDAURA (GOLD SALT)
MECHANISM OF ACTION

The precise mechanism of gold salts is incomprehensible. A few impacts could contribute, Gold– albumin organizations are phagocytosed by macrophages and polymorphonuclear leukocytes and collective in their lysosomes, where gold represses lysosomal compounds that have been involved in causing joint harm. Gold ties to sulphhydryl gatherings and restrains sulfhydryl– disulfide exchange in immunoglobulin and supplement, which could impact resistant procedures[50].

THE EFFECTIVENESS OF RAIDAURA

Ridaura applies their beneficial impact in diminishing rheumatoid aggravation is recommended by thinks about describing an effect of these specialists on the rheumatoid factor (RF). After results of the multicenter controlled trial of gold salt treatment led by the Domain Rheumatism Council[51]. Demonstrated a remarkable reduction in RF titer in treated patients. Also, clinical trials directed by Hartung[51]Michotte and Van- ~lype[53],~ and Ziff, Hess, and Baum[54]. Have exhibited a lessening in serologic titer correspondent with gold salt treatment. These discoveries proposed that gold salt may influence immunologic marvels and, in this manner, adjust rheumatoid aggravation[55].

SIDE EFFECTS OF RAIDAURA

Rashes are an indication to stop treatment, as they can progress to detaching. Photosensitive presentations and urticarial are as often as possible gone before by shivering. Glomerular harm can cause nephrotic scatter. Treatment must be postponed if more than a trace of proteinuria is accessible, and should not be continued until the point that the pee is without protein. Blood dyscrasias (e.g. neutropenia) can develop rapidly[56].

NEW METHODS FOR DIAGNOSIS OF RHEUMATOID ARTHRITIS

1. **The Dorsal 4-finger Strategy (DFFT)** is another and reliable technique for inspecting metatarsophalangeal (MCP) joints in patients with rheumatoid arthritis and is better corresponded with ultrasound (US) than the usual 2-finger method (TFT) [57].

2. **Customary Radiography (CR)** is the standard result measure of essential joint harm in rheumatoid arthritis (RA), in clinical trials and also in clinical hone[58, 59,60]. Moreover, the nearness of radiographic bone breakdowns is one of the symptomatic criteria for rheumatoid arhtiris[61]. The cutting-edge treatment system in rheumatoid arthritis includes utilization of active treatment to restrict irritation and bound joint pulverization, trailed by provoking treatment alterations on the off chance that it is apparent that these treatment objectives are not being accomplished[62.63].

NEW APPROACHES FOR DIAGNOSIS

Electronic Dolorimeter is the new approach for measuring joint inflammation. Thirty rheumatoid arthritis patients were evaluated using the Electronic Dolorimeter and were compared with standard methods of measuring joint inflammation. The Electronic Dolorimeter was associated with less interobserver error than manual techniques, but conventional methods were sensitive to change and were less costly.
Martin Vigorimeter (an aneroid manometer associated with a compressible elastic globule). Seventeen rheumatoid arthritis patients were learned at intervals of 1 to four months. The Vigorimeter indicated great test-retest and interobserver dependability also, related altogether with joint checks. Regular grasp quality estimations utilizing a pulse cover have high interobserver infidelity, and straightforward institutionalized instruments, for example, the Martin Vigorimeter might be more helpful in deciding long tow result in RA patients[64].

NEW TREATMENT FOR RHEUMATOID ARHTRITIS
KINASE INHIBITORS

Treatment of rheumatoid joint inflammation (RA) has significantly enhanced in the course of the most recent period with the associate of cytokine inhibitors with TNFa, IL-1, and IL-6. Endeavours to build up a slight oral particle with comparable viability and similar security to biologics have been progressing for rather a long time, with small accomplishment as of not long ago. P38 MAPK (microtubule-associated protein kinase) inhibitors. There are three notable groups of MAPKS-extracellular flag controlled kinase (ERK), c-JUN N-terminal kinase (JNK), and p38. The MAP kinases are intracellular enzymes that transmit a signal to the nucleus resulting in quality translation. p38 MAPK (microtubule-associated protein kinase) is a crucial controller of professional provocative cytokine creation. Changed cell stresses, for example, incendiary cytokines, pathogens, and development factors pass kinases, which control the outflow of critical qualities bringing about transcriptional actuation of TNFa, IL-1 and IL-6. Phosphorylated enacted p38 MAPK is likewise found in the synovial coating and endothelium of vessels in RA synovium. Several studies have demonstrated that hindrance of p38 MAPK (microtubule-associated protein kinase) stifles the creation of incendiary cytokines, and preclinical creature models have exhibited a decrease in paw swelling and joint harm[65].

NEW ORAL COMPOUND FOR THE TREATMENT OF RHEUMATOID ARHTIRIS

Auranofin is the new oral gold compound for the treatment of rheumatoid arthritis. Eight patients with rheumatoid joint pain were distributed with SK&F D-39162 (auranofin), another oral gold compound which was successful in restricting adjuvant-initiated joint pain. Clinical and humoral parameters were considered among a 3-month time of medication organization took after by a 3-month duration under wrong treatment. The medication was integrated, very much tolerated, and its activity was slowed by a drop in the mean IgG (Immunoglobin G) blood levels in the third seven day give of treatment joined by clinical change following five weeks of oral gold admission. Together with IgG changes, an increase of the albumin proportion was seen, and also a diminishing of tx2-globulin and rheumatoid factor titers, From an aggregate number of 60 swollen joints discovered at first in the eight patients, just 17 were swollen at week 12 and nine at week 15. Although the number of patients treated was too slight to permit clear decisions, a following report under wrong treatment of clinical and research facility changes in similar patients among an additional 3-month period demonstrated that IgG serum levels quickly returned going before an erupt of infection action after withdrawal of the medication. This affirmed the next part in cause-impact connection played by the new oral gold compound[66].

DURATION OF TREATMENT

Rheumatoid joint pain tends to be a long-lasting illness. Mixes of methotrexate and the new biologic operators can quick reduction in 30 to 40 per cent of patients with rheumatoid joint inflammation, in any case, for most patients, huge ailment holds on anyhow treatment[67,68]. Complete reduction once in a while happens, in clinical trials, change has been followed utilizing the ACR change criteria, regularly ACR 20, ACR 50, or ACR 70. The numbers declare to the level of change in the associated criteria: number of slight joints, number of swollen joints, common sickness action (as evaluated by the patient or by an eyewitness), irritation level, physical handicap score, and intense stage reaction (as estimated by CRP or ESR)[69]. For the individual patient, wellbeing evaluation surveys might be a more valuable method for assessing sickness movement, for example, European League against Rheumatism reaction criteria for rheumatoid joint inflammation and different day by day action score overviews[70, 71,67,68,69]. Radiologic evaluation scales are additionally valuable[70, 71, 68]. Treatment should to be guided by an individual clinical reaction to different mediations. Although adjustments in haemoglobin, ESR, also, CRP may fill in as accommodating markers of response to treatment, platelet tally, and rheumatoid factor levels have been found not to relate well. As a rule of RA, the patient has reductions and increases of the side effects. This implies that there are timeframes when the patient "can rest easy" and times when the patient "feels more awful." There are likely circumstances that a patient with RA "feels cured." It is imperative to comprehend that there are not very many patients that have finish reduction of the infection and it is fundamental that the RA persistent does not stop the treatment program built up by capable therapeutic services experts. Once in a while does the ailment "leave," although now and again the side effects may briefly dispatch [72].

CONCLUSION

For Prompt and accurate diagnosis of rheumatoid arthritis, early antagonistic treatment including disease-modifying Antirheumatic drugs or biologics, control on symptoms, and close monitoring of disease state and medication toxicity are the keys to effective management of the patient with rheumatoid arthritis. The ability of NSAIDs to thereby inhibit the activation of inflammatory cells such as the neutrophil may contribute to the anti-inflammatory properties of this class of drugs. Advancement of rheumatoid joint inflammation treatment is probably going to be further endeavors to prompt abatement in early illness by upgrading the underlying medications utilized.

REFERENCES

[1] Salerno L et al. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 2002; Vol. - 8: Pp. - 177–200.

[2] Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; Vol. - 359: Pp-1173–77.

[3] Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: Pp.-26–34.

[4] Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity, and mortality of rheumatoid arthritis. Scand J Rheumatol Suppl 1989; Vol.-**79**: Pp. - 67–96.

[5] Devine Beth Emily, Sean D. Sullivan, and definition of rheumatoid arthritis. The effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach, Vol. - 31, 2011 Pp. - 39-40.

[6] Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol, 1995; Vol. - 34(S2): Pp.-59– 73.

[7] Firestein GS. Etiology and pathogenesis of rheumatoid arthritis: Kelley"s Textbook of Rheumatology. 7th ed. Philadelphia; WB Saunders: 2005, Pp. - 996–1042.

[8] Rothschild BM, Rothschild C, Helbling M. Unified theory of the origins of erosive arthritis: conditioning as a protective/directing mechanism. J. Rheumatol, 2003; Vol. - 30(10): Pp. - 2095–102.

[9] Spindle K (1995), the man in the ice, Phoenix: 1995. Pp. - 178–184, ISBN 0 75381 260 6.

[10] Sokka T. Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice. Scand J Rheumatol Suppl, 2011; Vol.-125: Pp.-23-7.

[11] Balandraud N, Meynard JB, Sooran H, Mugnier B, Reviron D, Roudier J, Roudier C. Epstein Barr virus load in the peripheral blood of patients with rheumatoid arthritis. Arthritis and Rheumatism, 2003; Vol.-48: 1223-8.

[12] Ritter M, Lewis D Lionel, Introduction- Inflammation, Non-Steroidal anti-inflammatory drugs, The textbook of clinical pharmacology and therapeutics (2008),5th edition, Pp.- 167.

[13] Smith WL. Prostanoid biosynthesis and the mechanism of action. Am J Physiol. 1992; Vol.-263: Pp.-F118 –F191.

[14] Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996; Vol.-270: Pp.-G393–G400.

[15] Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996; Vol.-271: Pp.-15810 –15814.

[16] Hawkey CJ. COX-2 inhibitors. Lancet. 1999; Vol.-353: Pp.-307–314.

[17] Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, Smith WL. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 1995; Vol.-270: Pp.-10902–10908.

[18] Smith WL. Prostanoid biosynthesis and the mechanism of action. Am J Physiol. 1992; Vol.-263: Pp.-F118 –F191.

[19] Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. MRNA splicing regulates expression of a mitogen-responsive gene encoding prostaglandin synthase. ProcNatlAcadSci U S A. 1991; Vol.-88: Pp.-2692–2696.

[20] Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homolog. J Biol Chem. 1991; Vol. - 266:Pp.-12866 –12872.

[21] Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets, I: acetylation of a particulate fraction protein. J Clin Invest.1975; Vol.-56: Pp.-624–632.

[22] Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995; Vol.-2: Pp.-637– 643.

[23] Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol. 1998; Vol.-38: Pp.-97–120.

[24] Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and -2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995; Vol.-15: Pp.-179 –194.
[25] Insal PA, The salicylates, In Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman and Gilman's A, editors, Goodman and Gilman's the pharmacological basis of therapeutics 9th Edition, New York: McGraw-Hill; 1996. pp.: - 635-31.
[26] Insel PA. The salicylates. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, editors. Goodman and Gilman are the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. Pp.-625–31.
[27] Insel PA. The salicylates. In: Hardman JG, Limbird LE, MolinoffPB, Ruddon RW, Goodman Gilman A, editors. Goodman and Gilman are the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. Pp. - 625–31.
[28] F.J. Ingelfinger, "The Side Effects Of Aspirin" N Engl. J Med 1974; Vol.290:1196-1197.
[29] Van Hecken A, Schwartz JI, and Depre M, et al. the Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; Vol.-40: Pp.-1109-20.
[30] Tegeder I, Lotsch J, Krebs S, et al. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. ClinPharmacol Ther 1999; Vol. - 65: Vol.-533-44.
[31] Wittenberg RH, Willburger RE, Kleemeyer KS, et al. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 1993; Vol.-36: Pp.-1444-50.
[32] Ku EC, Lee W, Kothari HV, et al. The effects of diclofenac sodium on arachidonic acid metabolism. Semin Arthritis Rheum 1985; Vol.-15: Pp.-36-41
[33] Ku EC, Lee W, Kothari HV, et al. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 1986; Vol.-80:Pp.-18-23.
[34] Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal anti-inflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy 2005; Vol.-25:Pp.-18-25.
[35] Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheum 1996; Vol.-102: Pp.-9-21.
[36] Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; Vol.-15:Pp.-2057-72.
[37] Robert Burman, Randy Gregg, Lippincott- raven publishers, "clinical journal of sports medicine" Lippincott-raven publishers-1998.
[38] Lin-Fen Hsieh, Chang-Zern Hong, "Efficacy and Side Effects of Diclofenac Patch in Treatment of Patients with Myofascial Pain Syndrome of the Upper Trapezius", Side Effects of Diclofenac, Vol.-39, 2010:Pp.-120-121.
[39] Cronstein BN, Eberle MA, Gruber HE, *et al.* Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. ProcNatlAcadSci USA 1991:Vol.-88:Pp.-241-5.
[40] Vinod Chandran, Catherine T Schentag and Dafna D Gladman "The Journal of Rheumatology" March 2008, Vol.-35 (3), Pp.-469-471.
[41] James M. Ritter, Anti-Inflammatory drugs and the treatment of Arthritis, "The Textbook of Clinical Pharmacology and therapeutics", 5TH Edition, 2008: Pp:-170.
[42] Cherwinski, H. M., McCarley, D., Schatzman, R., Devans, B., and Ransom, J. T., The immunosuppressant leflunomide inhibits the progression through the cell cycle by a novel mechanism. J. Pharm. Exp. Therapeutics 272, 460–470, 1995.
[43] Fairbanks, L. D., Bofill, M., Ruckemann, K., and Simmonds, H. A., Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. Vol. - 270, Pp.-29682–29689, 1995.
[44] Cherwinski, H. M., McCarley, D., Schatzman, R., Devans, B., and Ransom, J. T., The immunosuppressant leflunomide inhibits the progression through the cell cycle by a novel mechanism. J. Pharm. Exp. Therapeutics Vol.-272, Pp.-460–470, 1995.
[45] Silva, H. T., Cao, W., Shorthouse, R., and Morris, R. E., Mechanism of action of leflunomide: In vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant. Proc. Vol.-28, Pp. - 3082–3084, 1996.
[46] Siemasko, K. F., Chong, A. S., Williams, J. W., Bremer, E. G., and Finnegan, A., Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation Vol.-61, Pp.-635–642, 1996
[47] Morris, R., Huang, X., Cao, W., Zhjeng, G., and Shorthouse, R., Leflunomide (HWA 486) and its analog suppress T and B-cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey recipients. Transplant. Proc. Vol.-27, Pp.-445–447, 1995.
[48] Vlastimir Mladenovic, Zlatko Domljan, "Safety and Effectiveness of Leflunomide In The Treatment Of Patients With Active Rheumatoid Arthritis," Arthritis & Rheumatism Vol.-38, No. 1 I, November 1995, Pp. - 1595-1603.
[49] Vandana Mehta, "Saurav Kisalay, Indian J Dermatol Venereol Leprol", Side effects of leflunomide, 2009: Vol. - 75: pp.: - 423-424.
[50] Lewis D Lionel, Ritter M James, "A Textbook of Clinical Pharmacology and therapeutics" "Mechanism of action of gold salts," 5th Edition, Pp.- 170.
[51] Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Ann. Rheum. Dis. 19:95, 1960.
[52] Hartung, E. F.: The effect of chrysotherapy on the S.S.C.A.R. 9th Int. Congr. Rheumatol. Toronto, Canada, 1957. :
[53] Michotte, L., and Vanslype, J.: The influence of chrysotherapy followed by chloroquine therapy upon the hemagglutination reaction in rheumatoid arthritis. Acta Rheum. Scan. 5148, .1959.
[54] Ziff, M., Hess, E. V., and Baum, J.: Unpublished observations.
[55] Swartz, H. A., Christian, J. E., and Andrews, F. N.: Distribution of sulfur35- and gold- labeled gold thioglucose in mice. Amer. J. Physiol. 199:67, 1960.
[56] James M. Ritter, The Textbook of Clinical Pharmacology and Therapeutics, "anti-inflammatory drugs and the treatment of arthritis". 5th edition Pp.:-170.
[57] Omair MA, Akhavan P, Naraghi A, et al. The dorsal 4-finger technique: a novel methodtoexamine"http://www.jrheum.org/content/45/3/329.long". JRheumatol.2018; Vol.-45(3):329-334.
[58] American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; Vol.-46: Pp. - 328–46.

[59] Tugwell P, Boers M. OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: conclusion. J Rheumatol 1993; Vol.-20: Pp.-590.
[60] Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology prelimi2130 ØSTERGAARD et al. nary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; Vol.-36:Pp.-729–40.
[61] Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; Vol.-31: Pp.-315–24.
[62] American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; Vol.-46: Pp.-328–46
[63] Emery P. The optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol 1994; Vol.-33: Pp.-765–8.
[64] Elliott L. Semble, "New Approaches for Its Evaluation and Management", Arch Phys Med Rehabil I/ol 76, February 1995, Pp:-191.
[65] Stanley Cohen and Roy Fleischmann, "Kinase inhibitors: a new approach to rheumatoid arthritis treatment", Vol. - 22-Issue 3, Pp.- 330-335.
[66] Finkelstein, A. E., Walz, D. T., Batista, V., "Auranofin-New oral gold compound for treatment of rheumatoid Arthritis" Ann. Rheum. Dis. (1976) 35, Pp.-251.
[67] Fresenius HemoCare, Inc., New Hope for Rheumatoid Arthritis Patients. Press release, September 17: 1999.
[68] Moreland LW. Rheumatology and Immunology Therapy, Prosorba column Part 2004; Vol.-16: Pp.-731-732.
[69] Lee MS, Shin BC, Ernst E. Acupuncture for rheumatoid arthritis: a systematic review. Rheumatology, 2008; Vol. - 47 (12): Pp.-1747–53.
[70] Hurkmans E, van der Giesen FJ, VlietVlieland TPM, Schoones J, Van den Ende ECHM. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database of Systematic Reviews, 2009; 4. Art. No.: CD006853.
[71] Wright S, Ware M, Guy G. (2006). The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis (LTE). Rheumatology, 2006; Vol.-45 (6): Pp.-781.
[72] Albano S, Santana-Sahagan E, Weisman MH. Cigarette Smoking and Rheumatoid Arthritis. Semin Arthritis Rheum, 2001; Vol.-31: Pp.-146-159.